Open an account

Fortress Biotech

FBIOP · NASDAQ

$16.45−$0.22 (−1.32%)TodayMarket closed ·
Prev close $16.67

About FBIOP

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 78 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.

Employees
78
Headquarters
Bay Harbor Islands, Florida
Listed
Nov 17, 2011
Sector
Health Care
Industry
Biotechnology
Website
fortressbiotech.com

FBIOP key statistics

Market cap
64.37M
Price-earnings ratio
6.31
Dividend yield
0.77%
Average volume
14.86K
Volume
28.64K
Open price
$16.80
High today
$16.80
Low today
$15.06
52 Week high
$21.43
52 Week low
$6.27

Fortress Biotech (FBIOP) at a glance

As of Oct 23, 2026, Fortress Biotech (FBIOP) shares are priced at $16.45, giving the company a market cap of 64.37M, a price-to-earnings ratio of 6.31 and a dividend yield of 0.77%.

Today the stock has traded between $15.06 and $16.80. The current price is 9.2% above the day's low and 2.1% below its high.

Volume so far is 28.64K shares, above the average of 14.86K shares a day.

Over the past year Fortress Biotech has ranged from $6.27 to $21.43, and now sits 67% of the way up that range.

Fortress Biotech met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.08 per share against an estimate of -$0.204.

FBIOP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 48.4% on average.

  1. Q3 FY24: reported -$0.76 per share against an estimate of -$0.6069
  2. Q4 FY24: reported -$0.75 per share against an estimate of -$0.7684
  3. Q1 FY25: reported -$0.48 per share against an estimate of -$0.5049
  4. Q2 FY25: reported -$0.50 per share against an estimate of -$0.3672
  5. Q3 FY25: reported $0.11 per share against an estimate of -$0.4284
  6. Q4 FY25: reported -$0.01 per share against an estimate of $0.1122
  7. Q1 FY26: reported -$1.13 per share against an estimate of -$0.2244
  8. Q2 FY26: reported -$0.08 per share against an estimate of -$0.204

FBIOP news

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releaseGlobe Newswire

    Fortress Biotech to Participate in October 2024 Investor Conferences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.